WASHINGTON, D.C. - Brad Zakes, senior vice president for emerging companies and economic affairs at the Biotechnology Innovation Organization (BIO), released the following statement on passage of legislation reauthorizing the SBIR/STTR program:"The SBIR/STTR program has a long and proven track record of supporting and growing the most innovative American biotechnology companies. Since its inception, the program has helped bolster the type of early-stage companies that drive economic growth, medical innovation and job creation. For decades, this program has ignited innovative science and helped to fuel America's leadership in this critical sector.  We look to build on that success with new medicines, new research and new companies that position the U.S. for success for years to come. BIO applauds Congress for its leadership and for reauthorizing this important program."###About BIOBIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.